Formulation and Characterization of Self-Microemulsifying Drug Delivery System of Tacrolimus  
Duaa J Al-Tamimi* and Ahmed A. Hussein**

*Department of Pharmacy, Al-Rasheed University College, Baghdad, Iraq  
**Department of Pharmaceutics, College of Pharmacy, University of Baghdad, Baghdad, Iraq

Abstract

The present investigation aimed to formulate a liquid self-microemulsifying drug delivery system (SMEDDS) of tacrolimus to enhance its oral bioavailability by improving its dispersibility and dissolution rate. Four liquid SMEDDS were prepared using Maisine® CC as oil phase, Labrasol® ALF as surfactant and Transcutol® HP as co-surfactant based on the solubility studies of tacrolimus in these components. The phase behavior of the components and the area of microemulsion were evaluated using pseudoternary phase diagrams. The formulations were also assessed for thermodynamic stability, robustness to dilution, self-emulsification time, drug content, globule size and polydispersity index. The prepared SMEDDS formulations exhibited improved drug release compared to the pure drug powder. From this study, it was concluded that using a composition of 10% Maisine® CC, 67.5% Labrasol® ALF and 22.5% Transcutol® HP produced a liquid SMEDDS with good thermodynamic stability and enhanced in-vitro drug release profiles compared with pure tacrolimus powder. All which supports the use of self-micro emulsifying drug delivery systems as a promising approach to improve dispersibility, dissolution and stability of poorly soluble drugs like tacrolimus.

Keywords: SMEDDS, Microemulsion, Tacrolimus.

Introduction

Tacrolimus (FK506) is a selective calcineurin phosphatase inhibitor macrolide. It is the first-line agent used for preventing organ rejection in solid organ transplant patients. (1) Oral dosage forms such as capsules, tablets and granules for oral suspension are available of the drug and are preferred by patients due to their convenient administration. (2) However, being a biopharmaceutics classification system (BCS) class II drug, tacrolimus is poorly soluble in gastric pH leading to low gastrointestinal (GI) absorption and high inter- and intra-individual variations in pharmacokinetic parameters (3). Its chemical formula is C_{26}H_{23}NO_{7} and its molecular weight is 822 Da. Log P is 3.3. The average absolute bioavailability of tacrolimus was found to be about 21%, with a wide range of 4% to 89%. (4,5)

All which necessitated the development of an enhanced oral delivery system to overcome the low solubility of tacrolimus (4,5). Self-microemulsifying drug delivery systems (SMEDDS) are lipid-based formulations containing an isotropic mixture of oil, surfactant and cosurfactant that forms small oil-in-water (o/w) microemulsion upon contact with the aqueous medium of GI secretions under the mild agitation of peristaltic activity (6). The spontaneous transformation of SMEDDS along with the micro size of particles offer faster drug release profiles and a larger surface area for absorption, all leading to increased bioavailability; meaning that a smaller dose might be used to achieve the therapeutic effect with a reduction of GI irritation and other common side effects leading to improved patient compliance and overall therapeutic outcome (7).

DOI: https://doi.org/10.31351/vol30iss1pp91-100

Iraqi Journal of Pharmaceutical Science

91
This study aimed to formulate a tacrolimus-loaded liquid SMEDDS with an enhanced dissolution and consequently its oral bioavailability compared to the pure drug powder.

**Materials and Methods**

**Materials**

Tacrolimus was purchased from Hyper-Chem LTD CO (China). Labrasol® ALF, Transcutol® HP, laurolglycol FCC laurolglycol 90, peceol and Maisine® CC were donated by Gattefosse Co. (St. Priest, France). Castor oil was provided by now food, (USA). Tween 20 was obtained from SCRC (China). Tween 80 was obtained from Pure Chemistry (Germany). Cremophor EL, cremophor RH were purchased from Hyper-Chem LTD CO (China). PEG 200 was received from BDH limited Poole (England). PEG 400 from SCRC (China). Methanol and propylene glycol were bought from Sigma-Aldrich (Germany). Deionized water was purchased from J.T. Baker (Netherlands). All other chemicals were of analytical grade and used as supplied.

**Methods**

**Differential scanning calorimetry (DSC) analysis**

The process was carried out by weighing two milligram of the pure drug, sealing it in an aluminum pan and then placing in DSC instrument. The sample was heated at temperature up to 300 °C and at a rate of 10 °C/min, using nitrogen as blank gas.

**Solubility studies**

Tacrolimus was added in excess amounts to glass vials containing 2mL of each vehicle separately including oils, surfactants and cosurfactants, the components were thoroughly mixed for 10 minutes with a vortex mixer then shaken using a water bath shaker for 48 hours at 25±1°C followed by centrifugation at 3000 rpm for 20 minutes to separate the undissolved drug. Aliquots from the supernatants were then filtered by a 0.45 µm millipore filter. The resulting solution was then diluted with 100 mL methanol and analyzed using UV-visible spectrophotometer at λ_max 213 nm to measure its drug concentration. The analysis was done according the calculated λ_max and calibration curve.

**Construction of pseudoternary phase diagrams**

Pseudoternary phase diagrams of oil, surfactant/cosurfactant (Smix), and water were constructed using the aqueous titration method. The surfactant to cosurfactant mixtures were prepared in ratios of (1:1, 2:1, 3:1, 4:1) then mixed with oil in various weight ratios from 1:9 to 9:1 in multiple glass vials. The resulting homogeneous mixtures of oil/Smix were titrated with water using magnetic stirrer with 50 rpm and at room temperature. After each addition of water, the mixture was checked for phase clarity. The turbidity of different solutions samples would indicate the formation of a coarse emulsion. Whereas a clear isotropic solution sample would indicate the formation of a microemulsion. The formation of microemulsion regions was checked visually for turbidity–transparency–turbidity. When the system became turbid, titration was stopped and the percentage of oil, S_mix and water in 100 % w/w mixture were calculated and was utilized for the determination of the microemulsion region boundaries corresponding to the chosen value of oil and Smix ratio. The percentages of oil, surfactants to cosurfactants ratios and water in each system were determined and plotted on triangular coordinated using CHEMIX ternary plot software.

**Preparation of tacrolimus-loaded SMEDDS**

Tacrolimus (0.5mg) was dissolved inMaisine® CC oil with different ratios of Labrasol® ALF and Transcutol® HP in separate screw-capped glasses vials. They were stirred gently by vortex mixer (50 rpm). The resulting homogenous mixtures were then stored at room temperature. The concentration was 2mg/ml. The composition of tacrolimus liquid SMEDDS formulations are illustrated in Table 1.

**Characterization and evaluation of tacrolimus-loaded SMEDDS**

**Thermodynamic stability studies**

Assessing the physical stability of SMEDDS is essential to prevent drug precipitation and excipients phase separation and ensure a good bioavailability and therapeutic drug profile upon administration. Therefore, the prepared formulas were serially assessed by various thermodynamic stability tests with thorough visual observation for any changes in physical appearance.
Centrifugation test
The formulations underwent centrifugation at 3500 rpm for 30 minutes under observation. Stable formulations were then subjected to the freeze-thaw cycle.

Heating-cooling cycle (H/C cycle)
Six heating-cooling cycles were performed in which the formulas were placed for 48 hours in alternating temperatures of 4 and 45 °C. The formulas that exhibited no phase separations, creaming or cracking were subjected to centrifugation test.

Freeze-thaw cycle
The formulas were stored for 48 hours at alternating temperatures of -21 and +25 °C for three consecutive cycles.

Robustness to dilution and effect of pH
The formulations that passed all the thermodynamic studies were diluted with deionized water and 0.1 N HCl for 50, 100, 250 and 1000 times to simulate in-vivo conditions. The formulations were stored at room temperature for 24 hours then observed visually for any changes. (15)

Dispersibility test and self-emulsification time
The efficiency of SMEDDS formulations was assessed using the USP dissolution apparatus II. One mL of each formulation was mixed with 500 mL of deionized water at 37 ± 0.5 °C under stirring speed of 50 rpm. (16) The resulting solutions were visually evaluated using the grading system shown in Table 2. (17)

Table 2. Grading system of in-vitro performance of self-microemulsifying drug delivery system (dispersibility and self-microemulsification time).

| Grade | Time required for microemulsion formation | Appearance |
|-------|------------------------------------------|------------|
| A     | Rapidly forming emulsion (within 1 min). | Having a clear or bluish appearance |
| B     | Rapidly forming, (within 1 min).         | Slightly less clear emulsion, having a bluish-white appearance |
| C     | Formed within 2 min.                     | Fine milky emulsion |
| D     | Slow to emulsify (longer than 2 min).    | Dull, greyish-white emulsion having a slightly oily appearance |
| E     | Slow to emulsify (longer than 2 min).    | Formula exhibiting either poor or minimal emulsification with large oil globules present on the surface |

Droplet size analysis and polydispersity index (PDI) determination
Fine microemulsions were formed by diluting each stable SMEDDS formula with deionized water to 100 times under stirring with a magnetic stirrer at 37 °C. Dynamic light scattering method was used to analyze the particle size using particle size analyzer apparatus (Brookhaven, USA) of the resultant microemulsions and the PDI was accordingly calculated. (18)

Drug content determination
Each formula was dissolved in 100 mL methanol in a volumetric flask and thoroughly mixed. After appropriate filtration and dilution, UV–visible spectrophotometer was used to measure drug absorbance. (19)

In-vitro drug release studies
Using the USP dissolution apparatus–II, the in-vitro release profiles of all prepared formulations along with pure drug were obtained. The dissolution medium consisted of 0.1N HCl at 37±0.5 °C and 75 rpm. (20) Each tacrolimus-loaded SMEDDS formula was placed in a dialysis bag (molecular weight cutoff of 12000 Da), and a regular withdrawal of 5 mL aliquots at 10, 20, 30, 40, 50 and 60 minutes was done. Equal volumes of fresh dissolution media (0.1N HCl) were added to replace the withdrawn samples in order to maintain the volume constant and keep sink condition. The amount of drug dissolved was measured using UV–visible spectrophotometer according to the calibration curve. (21)

Statistical analysis
The results of the experiments were presented as a mean of triplicate samples± standard deviation (± SD). The in-vitro dissolution studies results were statistically evaluated using the similarity factor (f2) equation. The results of the f2 test range between 0 and 100. Two dissolution profiles are considered similar when the f2 value is ≥ 50. This method is more acceptable to compare dissolution profile when more than three or four dissolution time points are available. (22)

\[ f_2 = 50 \times \log \left[ 1 + \frac{1}{n} \sum_{i=1}^{n} \left| R_i - T_i \right|^2 \right]^{-0.5} \times 100 \]

Results and Discussion
Differential scanning calorimetry (DSC)
The DSC was performed to determine the crystalline state of the drug and to provide specific information about the physicochemical status of tacrolimus. In addition, to evaluate the thermotropic properties and thermal behavior of tacrolimus.
The DSC thermogram of pure tacrolimus shows a sharp endothermic at 134.43 °C, corresponding to its melting point, which lies within the melting point readings of that reported in the references, which are from 126 °C to 135 °C (1), and inferring the presence of the crystalline form of the drug as shown in Figure 1.

**Figure 1. DSC thermograms of pure tacrolimus**

**Solubility studies**

Assessing the extent of the solubility of tacrolimus in the different microemulsion components is an essential step in formulating SMEDDS, as it greatly affects the physicochemical characteristics and drug loading capabilities of the SMEDDS formulations. (24) In this study, the highest solubility of tacrolimus was observed in Maisine® CC as oil phase, Labrasol® ALF as surfactant and transcutol as cosurfactant. These components were consequently chosen for further assessment. The analysis was done according the calculated λ_max and calibration curve as illustrated below in Figures 2 and 3. The solubility studies are shown in Figure 4.

**Figure 2. Tacrolimus UV-spectrum in methanol.**

**Figure 3. Tacrolimus UV calibration curve in methanol**
Figure 4. Solubility studies of tacrolimus (a) in various oils; (b) in various surfactants; (c) in various cosurfactants.

Construction of pseudoternary phase diagram

Pseudoternary phase diagrams were utilized to determine the optimal components concentration needed to create stable SMEDDS formulas that could withstand the aqueous dilution effects of the gastrointestinal system without losing solvent and microemulsifying capacity.\(^{(25)}\)\(^{(26)}\)

The pseudoternary phase diagrams of the various formulas with different Smix ratios are illustrated in Figure 5. The comparison of these phase diagrams shows that a higher concentration of labrasol corresponded with a larger microemulsions area indicating a higher emulsifying efficacy.

This could be attributed to the fact that the surfactants stabilizes the oil-water interface and its concentration increased at the interface upon decreasing the oily content in the ternary system. Thus, small size of the generated emulsions.\(^{(27)}\)

In addition, the reports indicate that a high HLB value of surfactant facilitates the formation of a stable microemulsion.\(^{(28)}\)

Figure 5. Pseudoternary phase diagram of Smix (a) (4:1); (b) (3:1); (c) (2:1); (d) (1:1)
**Preparation of tacrolimus-loaded SMEDDS**

Different concentrations of surfactant and cosurfactant were added to Maisine® CC oil in a fixed oil: Smix ratio of 1:9 as shown in table 1.

In all formulations, while simultaneously increasing and decreasing the concentrations of oil, surfactant and co-surfactant, respectively, Smix was held at fixed ratios.

The prepared formulas demonstrated a clear, homogeneous appearance with no change in the phase behavior or drug precipitation upon storage before characterization.

**Characterization and evaluation of tacrolimus-loaded SMEDDS**

*Thermodynamic stability studies*

All the prepared SMEDDS formulations passed the centrifugation, heating-cooling cycles and freeze-thawing cycles tests as shown in Table 3, which indicates their thermodynamic stability under extreme conditions.

**Table 3. Thermodynamic stability studies of tacrolimus liquid self-microemulsifying drug delivery systems**

| Formula | Centrifugation test | Heating-cooling cycles test | Freeze-thawing cycles test |
|---------|---------------------|----------------------------|---------------------------|
| F1      | Pass                | Pass                       | Pass                      |
| F2      | Pass                | Pass                       | Pass                      |
| F3      | Pass                | Pass                       | Pass                      |
| F4      | Pass                | Pass                       | Pass                      |

**Robustness to dilution and effect of pH**

The formulations showed excellent robustness to dilution and pH effect, as no drug or phase separation was observed in any of the prepared emulsions after 24 hours of dilution in 0.1N HCl and deionized water, as illustrated in table 4. These results reveal the high solubilizing properties of the SMEDDS components and their resilience to changes in pH and ionic strength, probably due to their non-ionic nature. (29)

**Table 4. Robustness to dilution of various tacrolimus liquid self-microemulsifying drug delivery systems**

| Formula | Phase separation | Drug precipitation |
|---------|------------------|---------------------|
|         | 0.1N HCl         | Deionized water     |
| F1      | pass             | pass                |
| F2      | pass             | pass                |
| F3      | pass             | pass                |
| F4      | pass             | pass                |

**Dispersibility test and self-emulsification time**

All the prepared formulas spontaneously produced clear grade A microemulsions in less than one minute as shown in Table 5. Higher Labrasol® ALF concentration was associated with reduced self-emulsification time. This may be attributed to its ability to enhance dispersion and emulsion formation by reducing the interfacial tension between the oil and aqueous phase. (31)

**Table 5. Dispersibility and self-micro emulsification time of tacrolimus liquid self-microemulsifying drug delivery systems**

| Formula | Grade | Emulsification time (sec) | Formula | Grade | Emulsification time (sec) |
|---------|-------|----------------------------|---------|-------|----------------------------|
| F1      | A     | 23 ± 1.12                  | F3      | A     | 16 ± 1.72                  |
| F2      | A     | 20 ± 1.96                  | F4      | A     | 15 ± 2.14                  |

**Droplet size analysis and polydispersity index (PDI) determination**

Assessing droplet size and PDI values is crucial in evaluating SMEDDS formulas as they directly affect the absorption of the drug and its uniformity after dilution. (14) In this study, all prepared formulations had acceptable droplet size measurements and PDI values closer to zero indicating good homogeneity and uniformity, as shown in Table 6 and presented in Figure 6.

Similar results obtained from Juno Yoo et al. who studied the effect of different properties...
(labrasol to transcutol concentration is one of these factors) on self-emulsifying drug delivery system and found that when transcutol concentration increased to up to 35%, the droplet size will be increased.\(^{32}\)

Table 6. Droplet size measurement and polydispersity index (PDI) of tacrolimus liquid self-microemulsifying drug delivery systems

| Formula | Particle size ± SD (nm) | Polydispersity index |
|---------|-------------------------|----------------------|
| F1      | 44.3 ± 1.073            | 0.005                |
| F2      | 32.3 ± 1.073            | 0.005                |
| F3      | 29.5 ± 1.073            | 0.005                |
| F4      | 34.2 ± 1.141            | 0.018                |

Figure 6. Droplet size and polydispersity index of of tacrolimus liquid self-microemulsifying drug delivery systems (a) F1; (b) F2; (c) F3; (d) F4.

**Drug content determination**

The drug content in all the prepared formulations exceeded 98% and was within the USP-recommended range of 85%-115%. as shown in Table 7. These results indicate the uniform dispersion of tacrolimus within SMEDDS.\(^{20}\)

Table 7. The drug content percent of tacrolimus liquid self-microemulsifying drug delivery system (mean ±SD) n=3

| Formula | Drug content % | Formula | Drug content % |
|---------|----------------|---------|----------------|
| F1      | 98.84 ± 0.175  | F3      | 99.76 ± 0.081  |
| F2      | 99.53 ± 0.122  | F4      | 98.44 ± 0.093  |

**In-vitro drug release studies**

In order to evaluate the actual drug release of formulations, the proportion of drug dissolved in the aqueous medium should be separated from that associated with the emulsion.\(^{34}\)

For this purpose, the dialysis bag method is utilized to permeate the dissolved drug only and enable a more accurate estimation of drug release from the SMEDDS formulations. In this study, a dialysis bag with a very small pore size (molecular weight cutoff of 12000 Da) was used to ensure a large surface area of particles subjected to the dissolution medium.\(^{35}\) It was soaked overnight in 0.1 N HCl dissolution medium to reach equilibrium.\(^{36}\)

The calibration curve of tacrolimus in 0.1 N HCL shown in Figure 7. The in-vitro release profiles of the prepared formulas along with that of the pure drug were assessed in 0.1 N HCl over one hour as shown in Figure 8. All the prepared liquid SMEDDS formulations had dissimilar release profiles relative to the pure drug (\(f_2 <50\)). Formulation F3 showed the highest release rate (98.71%) followed by F2 (97.33%) while the release rate of the pure drug (19%) was the lowest among all tested formulations. The noticeable increase in the in-vitro drug release profiles could be explained by the rapid self-emulsification properties of SMEDDS and their ability to generate
microemulsions with fine droplet size upon dilution. \(^{(37)}\)

Furthermore, it could be observed from the figures that the particle size of the produced emulsion greatly affects the drug release rate, which could be explained by the droplet size-dependent release of tacrolimus from F3 formulations \(^{(38)}\), suggesting that formulations with smaller particles possess a higher release rate and vice versa, which explains why formulations F3 has the highest release \(^{(39,40)}\).

The in-vitro release rate and extent enhancement could be attributed to the SMEDDS fast spontaneous emulsification properties and the production of a small globule size with a high surfactant concentration \(^{(37)}\).

Figure 7. Tacrolimus UV calibration curve in 0.1 N HCL.

Figure 8. In-vitro release profiles of tacrolimus-loaded SMEDDS formulae compared with pure tacrolimus.

Conclusions

From this study, it is concluded that the liquid SMEDDS containing 10% Maisine® CC, 67.5% Labrasol® ALF and 22.5% transcutol showed good thermodynamic stability and a globule size in the nanoemetric range. The new liquid SMEDDS showed enhanced in-vitro drug release profiles compared with pure tacrolimus powder, which confirms the enhancing characteristics of the SMEDDS components and provide a potential for higher absorption and bioavailability.

References

1. Kino T, Hatanaka H, Miyata S, Inamura N, NISHIYAMA M, YAJIMA T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. The Journal of antibiotics 1987;40(9):1256–65.

2. Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations–opportunities and limitations. Drug Discovery Today: Technologies 2012;9(2):e87–95.

3. Park Y-J, Ryu D-S, Li DX, Quan QZ, Oh DH, Kim JO, et al. Physicochemical characterization of tacrolimus-loaded solid dispersion with sodium carboxymethyl cellulose and sodium laurel sulfate. Archives of pharmacal research 2009;32(6):893–8.

4. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clinical pharmacokinetics 1995;29(6):404–30.

5. Wallemacq PE, Furlan V, Möller A, Schäfer A, Studler P, Firdaous I, et al. Pharmackinetics of tacrolimus (FK506) in paediatric liver transplant recipients. European journal of drug metabolism and pharmacokinetics 1998;23(3):367–70.

6. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomedicine & pharmacotherapy 2004;58(3):173–82.

7. Jeevana JB, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. Journal of young pharmacists: JYP 2011;3(1):4.

8. Saritha D, Bose P, Nagaraju R. Formulation and evaluation of self-emulsifying drug delivery system (SEDDS) of ibuprofen. IJPSR 2014;5:3511–9.

9. Patel PV, Patel HK, Panchal SS, Mehta TA. Self micro-emulsifying drug delivery system of tacrolimus: Formulation, in vitro evaluation and stability studies. International journal of pharmaceutical investigation 2013;3(2):95.

10. Shafiq S, Shaakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. European Journal of Pharmaceutics and Biopharmaceutics 2007;66(2):227–43.

11. Atef E, Belmonte AA. Formulation and in vitro and in vivo characterization of a phentoin self-emulsifying drug delivery system (SEDDS). European Journal of Pharmaceutical Sciences 2008;35(4):257–63.

12. Kamble M, Borwandkar VG, Mane SS, Omkar R. Formulation and evaluation of lipid based nanoemulsion of glimepiride using self-emulsifying technology. Indo Am J Pharm Res 2012;2:1011–25.

13. Sapra K, Sapra A, Singh SK, Kakkar S. Self emulsifying drug delivery system: A tool in solubility enhancement of poorly soluble drugs. Indo Global J Pharm Sci 2012;2(3):313–32.

14. Sohn Y, Lee SY, Lee GH, Na Y-J, Kim SY, Seong I, et al. Development of self-
microemulsifying bilayer tablets for pH-independent fast release of candesartan cilexetil (Internet). 2012 (cited 2020 Mar 30);Available from: https://www.ingentaconnect.com/content/govir/ pharmaz2012/00000067/00000001/art00006
15. Patel AR, Vavia PR. Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J 2007;9(3):E344–52.
16. Zhang P, Liu Y, Feng N, Xu J. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. International Journal of Pharmaceutics 2008;355(1):269–76.
17. Khoo S-M, Humberstone AJ, Porter CJH, Edwards GA, Charman WN. Formulation design and bioavailability assessment of lipidic self-emulsifying formulations of halofantrine. International Journal of Pharmaceutics 1998;167(1):155–64.
18. Sharma S, Suresh PK. Formulation, In Vitro Characterization and Stability Studies of Self Microemulsifying Drug Delivery Systems of Domperidone. 2010;8.
19. Yadav PS, Yadav E, Verma A, Amin S. Development, characterization, and pharmacodynamic evaluation of hydrochlorothiazide loaded self-nanoemulsifying drug delivery systems. The Scientific World Journal (Internet) 2014;2014. Available from: https://www.hindawi.com/journals/tswj/2014/274823/
20. USP 32 NF 27: United States Pharmacopeia (and) National Formulary, Supplement 2. United States Pharmacopeial Convention; 2009.
21. Deshmukh A, Nakhat P, Yeole P. Formulation and in-vitro evaluation of self microemulsifying drug delivery system (SMEDDS) of Furosemide. Der Pharmacia Lettre 2010;2(2):94–106.
22. Huang Y-B, Tsai Y-H, Yang W-C, CHANG J-S, WU P-C. Guidance for industry, dissolution testing of immediate release solid oral dosage forms Guidance for industry, dissolution testing of immediate release solid oral dosage forms, 1997. Biological & pharmaceutical bulletin 2004;27(10):1626–9.
23. Sugibayashi K. Skin Permeation and Disposition of Therapeutic and Cosmeceutical Compounds. Springer; 2017.
24. Humberstone AJ, Charman WN. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Advanced drug delivery reviews 1997;25(1):103–28.
25. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. European Journal of Pharmaceutical Sciences 2000;11:S93–8.
26. Kallakunta VR, Eedara BB, Jukanti R, Ajmeera RK, Bandari S, A Gelucire 44/14 and labrasol based solid self emulsifying drug delivery system: formulation and evaluation. Journal of Pharmaceutical Investigation 2013;43(3):185–96.
27. Mahmoud H, Al-Suwayeh S, Elkadi S. Design and optimization of self-nanoemulsifying drug delivery systems of simvastatin aiming dissolution enhancement. African journal of pharmacy and pharmacology 2013;7(22):1482–500.
28. Müllertz A, Ogbonna A, Ren S, Rades T. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. Journal of pharmacy and pharmacology 2010;62(11):1622–36.
29. Li P, Ghosh A, Wagner RF, Krill S, Joshi YM, Serajuddin AT. Effect of combined use of nonionic surfactant on formation of oil-in-water microemulsions. International journal of pharmaceutics 2005;288(1):27–34.
30. Jannin V, Benhaddou H, Dumont C, Chevrier S, Chavant Y, Demarne F, et al. Establishment of a Binary Phase Diagrams Database for the Development of Self-emulsifying Lipid-Based Formulations. 2014;
31. Khan F, Islam MD, Roni MA, Jalil R-U. Systematic development of self-emulsifying drug delivery systems of atorvastatin with improved bioavailability potential. Scientia pharmaceutica 2012;80(4):1027–44.
32. Yoo J, Baskaran R, Yoo B-K. Self-nanoemulsifying drug delivery system of lutein: physicochemical properties and effect on bioavailability of warfarin. Biomolecules & therapeutics 2013;21(2):173.
33. Patil P, Patil V. Formulation of a self-emulsifying system for oral delivery simvastatin. In: In vitro and in vivo evaluation, Acta. Pharm. 57: 111–122 (2007). www.arpb.info Page 8 Bhargava et al., ARPB, 2011; Vol 1(1) ISSN 2250 - 0744 (Review Article.
34. Woo JS, Kim T-S, Park J-H, Chi S-C. Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch Pharm Res 2007;30(1):82–9.
35. Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. International journal of nanomedicine 2010;5:101.
36. Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. European Journal of Pharmaceutics and Biopharmaceutics 2006;63(3):288–94.

99
37. Kang BK, Lee JS, Chon SK, Jeong SY, Yuk SH, Khang G, et al. Development of self-
microemulsifying drug delivery systems (SMEDDS) for oral bioavailability
enhancement of simvastatin in beagle dogs. International journal of pharmaceutics
2004;274(1–2):65–73.

38. Mantena AD, Dontamsetti BR, Nerella A. Formulation, optimization and in vitro
evaluation of rifampicin nanoemulsions. International Journal of Pharmaceutical
Sciences and Drug Research 2015;7(6):451–5.

39. Deshmukh A, Kulakri S. Novel self micro-
emulsifying drug delivery systems (SMEDDS)
of efavirenz. J Chem Pharm Res 2012;4:3914–
9.

40. Balakrishnan P, Lee B-J, Oh DH, Kim JO, Lee Y-I, Kim D-D, et al. Enhanced oral
bioavailability of Coenzyme Q10 by self-
emulsifying drug delivery systems. International journal of pharmaceutics
2009;374(1–2):66–72.